11:30am Bispecific Antibody-Drug Conjugates for Targeted Cancer Therapy
Time: 11:30 am
day: Bispecific ADC Seminar Day
Details:
- Acquired resistance presents a major challenge to the development of ADC drugs, and dual targeting may be one solution to overcome it
- GenSci’s novel ADC technology platform and robust bispecific ADC pipeline;
- GenSci139, a highly differentiated and potential best-in-class EGFR×HER2 BsADC, for targeted therapy in multiple solid tumors;
- GenSci143, a highly differentiated B7-H3 x PSMA bispecific and potential best-in-class ADC, for the treatment of mCRPC
